文献速递慢性肾脏病肾血管病与高血压

SGLT2抑制在糖尿病肾脏病中的作用——从机制到临床结局

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-03-02

本文综述了SGLT2抑制剂在糖尿病肾脏病中的作用机制与临床结局。SGLT2在近端小管重吸收约90%滤过葡萄糖,2型糖尿病中其适应性上调维持高血糖;抑制SGLT2可诱导尿糖排泄改善血糖控制,并改善体重、血压、血尿酸和肾小球高滤过。恩格列净心血管安全性试验显示可改善2型糖尿病合并心血管疾病患者的肾脏和心血管结局,获益可能超越降糖作用。

要点

  • SGLT2在肾近端小管重吸收约90%滤过葡萄糖,2型糖尿病中其上调维持高血糖。
  • SGLT2抑制剂通过诱导尿糖排泄改善血糖控制,患者生殖道感染增多。
  • 恩格列净改善2型糖尿病合并心血管疾病患者的肾脏和心血管结局。

核心结论

  • SGLT2抑制剂除降糖外,还可改善体重、血压、血尿酸和肾小球高滤过。
  • 恩格列净在2型糖尿病合并心血管疾病患者中改善肾脏和心血管结局,获益可能由降糖以外机制解释。

研究设计与样本

  • 本文为小型综述,介绍SGLT2抑制剂药物类别、现有肾脏和心血管结局数据,并讨论其肾脏生理效应如何解释这些数据。

主要发现

  • SGLT2在肾近端小管重吸收约90%滤过葡萄糖。
  • 2型糖尿病中SGLT2适应性上调参与维持高血糖。
  • SGLT2抑制剂诱导尿糖排泄,有效改善血糖控制,患者生殖道感染增多。
  • SGLT2抑制剂有利影响体重、血压、血尿酸和肾小球高滤过。
  • 恩格列净心血管安全性试验显示,在2型糖尿病合并心血管疾病患者中改善肾脏和心血管结局,且获益在治疗开始后迅速出现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease not only has become the leading cause for ESRD worldwide but also, highly contributes to increased cardiovascular morbidity and mortality in type 2 diabetes. Despite increased efforts to optimize renal and cardiovascular risk factors, like hyperglycemia, hypertension, obesity, and dyslipidemia, they are often insufficiently controlled in clinical practice. Although current drug interventions mostly target a single risk factor, more substantial improvements of renal and cardiovascular outcomes can be expected when multiple factors are improved simultaneously. Sodium-glucose cotransporter type 2 in the renal proximal tubule reabsorbs approximately 90% of filtered glucose. In type 2 diabetes, the maladaptive upregulation of sodium-glucose cotransporter type 2 contributes to the maintenance of hyperglycemia. Inhibiting these transporters has been shown to effectively improve glycemic control through inducing glycosuria and is generally well tolerated, although patients experience more genital infections. In addition, sodium-glucose cotransporter type 2 inhibitors favorably affect body weight, BP, serum uric acid, and glomerular hyperfiltration. Interestingly, in the recently reported first cardiovascular safety trial with a sodium-glucose cotransporter type 2 inhibitor, empagliflozin improved both renal and cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease. Because the benefits were seen rapidly after initiation of therapy and other glucose-lowering agents, with the exception of liraglutide and semaglutide, have not been able to improve cardiovascular outcome, these observations are most likely explained by effects beyond glucose lowering. In this mini review, we present the drug class of sodium-glucose cotransporter type 2 inhibitors, elaborate on currently available renal and cardiovascular outcome data, and discuss how the effects of these agents on renal physiology may explain the data.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. van Bommel EJM, Muskiet MHA, Tonneijck L, et al. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol. 2017. PMID: 28254770. doi:10.2215/CJN.06080616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。